Gastroenterology

Rezaie explains how IBS care has shifted from symptom-based treatment to targeted, mechanism-driven strategies.

New long-term data link antidepressant use in IBS to higher mortality risk. Rezaie explains key findings and clinical implications.

Q1 2026 GI updates include advances in IBD and IBS therapies, long-term data, and new insights into access challenges for younger patients.

Catch up on new IBD drug trial data, updated HE guidelines from the American College of Gastroenterology, and more.

Gerlud explains unmet needs in EPI, including underdiagnosed patient populations, and the intense pill burdens patients face.

Gerlud explains why exocrine pancreatic insufficiency is often missed, even in high-risk patients.

ACG's 24 new HE recommendations tackle ammonia testing, lactulose titration, protein intake, and transplant criteria for cirrhosis patients.

Kichler notes that EPI is frequently overlooked in patients with symptoms resembling IBD or celiac disease and offers key insights on diagnosis and management.

McDonald discusses new trial data suggesting an initial vancomycin taper may reduce early recurrence of C difficile infection.

Long discusses AFFIRM data showing strong clinical and endoscopic outcomes with SC risankizumab (Skyrizi) induction in Crohn’s disease.

Williams explains colorectal cancer screening options, persistent barriers to uptake, and strategies to improve screening rates.

Stay updated with the latest healthcare breakthroughs, FDA actions, and new trial data, in this week’s essential news roundup.

Catch up on durability data and real-world insight from trials across inflammatory bowel disease and short bowel syndrome.

Risankizumab achieved superiority for the co-primary and ranked secondary endpoints at week 12 for SC injection versus placebo.

David Rubin, MD, discusses rapid advances in IBD care, new therapies, multidisciplinary models, and the push toward precision GI medicine.

4-year LUCENT data show mirikizumab reduces UC-related hospitalizations and surgeries, supporting durable remission and potential disease modification.

Hurtado-Lorenzo discusses trial data showing time-restricted feeding in Crohn’s disease results in weight loss, symptom improvement, and microbiome changes.

SEQUENCE trial data highlight sustained 3-year clinical and endoscopic remission with risankizumab in anti-TNF–exposed Crohn’s patients.

Panaccione recaps interim PROFUNDUS data showing real-world efficacy and safety of upadacitinib (Rinvoq) for ulcerative colitis.

Hurtado-Lorenzo explains the growing interest in meal timing as a potential lifestyle intervention for Crohn’s and recent trial data supporting its utility in this patient population.

Barnes reviews 3-year VIVID-2 data showing durable remission, steroid-free control, and stable safety with mirikizumab in moderate-to-severe Crohn’s disease.

New data show limited uptake of SBS-specific ICD-10 codes, raising concerns about misclassification and the true burden of disease.

Survey findings highlight abdominal and bowel symptom control, affordability, and formulary or insurance coverage as factors driving perceptions and prescribing patterns of PERT.

Catch up on disparities in IBD care, a potential new IBS drug, new insight on diet’s role in Crohn’s disease care, & more.